These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25339808)

  • 21. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
    Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE; Rinella ME
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH).
    Takaki A; Kawai D; Yamamoto K
    Int J Mol Sci; 2014 Apr; 15(5):7352-79. PubMed ID: 24786095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
    Banini BA; Sanyal AJ
    Curr Opin Gastroenterol; 2017 May; 33(3):134-141. PubMed ID: 28346237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver-targeting drugs and their effect on blood glucose and hepatic lipids.
    Gastaldelli A; Stefan N; Häring HU
    Diabetologia; 2021 Jul; 64(7):1461-1479. PubMed ID: 33877366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management.
    Başaranoğlu M; Örmeci N
    Turk J Gastroenterol; 2014 Apr; 25(2):127-32. PubMed ID: 25003670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H; Dufour JF
    Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus. II. Treatment].
    Pár A; Wittmann I; Pár G
    Orv Hetil; 2022 May; 163(22):855-862. PubMed ID: 35895614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease.
    Machida T; Obara T; Miyazaki M; Inoue J; Mano N
    Ann Hepatol; 2022; 27(4):100699. PubMed ID: 35278680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).
    Surapaneni KM; Priya VV; Mallika J
    Eur Rev Med Pharmacol Sci; 2014; 18(18):2736-41. PubMed ID: 25317811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.
    Eshraghian A
    World J Gastroenterol; 2017 Nov; 23(42):7495-7504. PubMed ID: 29204050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease.
    Francque S; Vonghia L
    Adv Ther; 2019 May; 36(5):1052-1074. PubMed ID: 30888594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
    Connelly MA; Velez Rivera J; Guyton JR; Siddiqui MS; Sanyal AJ
    Aliment Pharmacol Ther; 2020 Aug; 52(4):619-636. PubMed ID: 32638417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. State of the art: treatment of nonalcoholic steatohepatitis.
    Pearlman M; Loomba R
    Curr Opin Gastroenterol; 2014 May; 30(3):223-37. PubMed ID: 24717764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological management of nonalcoholic fatty liver disease.
    Barb D; Portillo-Sanchez P; Cusi K
    Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P; Bush H; Younossi ZM
    Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?
    Musso G; Anty R; Petta S
    Curr Pharm Des; 2013; 19(29):5297-313. PubMed ID: 23394094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.